Genmab reported 514M in EBIT for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Agios Pharmaceuticals AGIO:US $ -97640000 3.5M
Amarin AMRN:US -37619000 9.31M
Amgen AMGN:US $ 2175M 325M
Artemis Alpha ATS:LN -10207000 58.81M
AstraZeneca AZN:LN 2.2B 673M
Bayer BAYN:GR 4.17B 704M
Biomarin Pharmaceutical BMRN:US $ 39.15M 9.82M
Exelixis EXEL:US $ 83.24M 33.4M
Fresenius Medical Care FME:GR 322M 111.18M
Galapagos GLPG:NA -76332000 55.19M
Genmab GEN:DC 514M 295M
GlaxoSmithKline GSK:LN 1.82B 600M
GN Store Nord GN:DC 132M 385M
Hikma Pharmaceutical HIK:LN 256M 23M
Immunogen IMGN:US $ -61053000 38.2M
Insmed INSM:US $ -100938000 513K
Lonza Group LONN:SW 667M 116M
Novartis NOVN:VX 3.32B 176M
Regeneron Pharmaceuticals REGN:US $ 1306.9M 20.3M
Seattle Genetics SGEN:US $ -133111000 61K
William Demant Holding WDH:DC 1.83B 243M